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odulation by Adrenergic Receptor Genotype
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OBJECTIVES In the present study, we aimed to evaluate the effect of adrenergic receptor polymorphisms on
the response of myocardium to measured levels of cardiac adrenergic drive, and to evaluate
whether polymorphisms of presynaptic adrenoceptors modified the rate of cardiac and
systemic release of norepinephrine.
BACKGROUND Heightened sympathetic activity plays an important pathophysiologic role in congestive heart
failure (CHF). Recently several functionally relevant polymorphisms of the 2-, 1-, and
2-adrenoceptors have been identified, and specific genotypes have been associated with the
incidence or clinical severity of CHF. These adrenoceptors are known to be located both
pre-synaptically (2 and 2) and post-synaptically (1 and 2), raising the possibility that
their association with clinical measures in CHF could be mediated either by modulation of
the cardiac response to a given level of adrenergic drive or by altering norepinephrine release
from sympathetic nerve terminals.
METHODS We determined the 1-, 2-, and 2C-adrenoceptor genotype in 60 patients with severe CHF
in conjunction with measurement of cardiac and systemic sympathetic activity using the
radiotracer norepinephrine spillover method.
RESULTS We showed a strong relationship (r  0.67, p  0.001) between heart rate and the level of
cardiac adrenergic drive, and heart rate for a given level of cardiac adrenergic drive was
substantially greater in patients with the Arg/Arg16 2-adrenoceptor polymorphism (p 
0.02), whereas no such relationship existed for polymorphisms of the 1-adrenoceptor. The
genotype of the 2C- and 2-adrenoceptors showed no relationship to the rate of norepi-
nephrine release from cardiac sympathetic nerves.
CONCLUSIONS For the first time, we show that 2-adrenoceptor polymorphisms significantly influence the
relationship between heart rate and cardiac adrenergic drive in CHF, but do not affect the rate
of norepinephrine release from sympathetic nerve terminals. (J Am Coll Cardiol 2004;44:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.0582008–15) © 2004 by the American College of Cardiology Foundation
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hn extensive body of evidence based on clinical trial data
nd human and animal neurochemical studies supports the
oncept that congestive heart failure (CHF) is characterized
y heightened sympathetic tone and that this exerts an
dverse influence on the progression and outcome of CHF
1–3). Despite the relative uniformity of these observations,
See page 2016
any issues with regard to the biology of the sympathetic
ervous system and the pharmacologic approaches that are
vailable to manipulate its activity (directly or indirectly)
emain unresolved. Among these questions are key issues
elated to the extent to which the sympathetic nervous
ystem should be inhibited or antagonized in CHF and,
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elbourne, Australia. This study was conducted with support from the Atheroscle-
osis Research Trust (UK) and the National Health and Medical Research Council of
ustralia.n
Manuscript received April 28, 2004; revised manuscript received June 23, 2004,
ccepted July 12, 2004.erhaps more importantly, the precise mechanism by which
-adrenoceptor antagonism exerts its beneficial actions in
HF. To this end, recent comparative studies of metoprolol
nd carvedilol (4), which show a relative benefit for the
onselective -adrenoceptor antagonist, suggest that the
2-adrenoceptor (and possibly -adrenoceptors) could play
significant role in the pathogenesis of CHF.
Within the myocardium, the 2-adrenoceptor is located
t both sympathetic pre-synaptic and post-synaptic neuroef-
ector junctions, unlike the 1-adrenoceptor, which is only
ost-junctional (5). In the post-synaptic location myocardial
-adrenoceptors are known to modulate heart rate and
ontractility, and in heart failure (HF) it has been shown
hat the 1-adrenoceptor undergoes relatively greater down-
egulation in comparison to the 2-adrenoceptor (6). At the
re-synaptic site, experimental data exist to suggest that the
2-adrenoceptor may facilitate the release of norepinephrine
rom nerve terminals, although this remains controversial.
n opposition to this facilitatory role, the 2-adrenoceptor
as been shown to inhibit the neuronal release of norepi-
ephrine (7,8). However, the precise functional status of
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November 16, 2004:2008–15 Adrenoceptor Genotype in CHFhese pre-synaptic receptors remains uncertain in CHF. In
ddition to pre-synaptic modulation, the rate of catechol-
mine release from sympathetic nerve terminals is clearly
nder the influence of central control mechanisms, and the
ntrasynaptic concentration of norepinephrine is modulated
y the neuronal norepinephrine transporter.
The clinical importance of understanding the interaction
etween cardiac sympathetic adrenergic drive and HF
athophysiology and outcome has been made even more
mportant with the recent discovery of functional polymor-
hisms of the 1-, 2-, and 2-adrenoceptors. In particular,
t has been demonstrated that polymorphisms of the 2C-
drenoceptor may be accompanied by a greater propensity to
HF (8,9), and that polymorphisms of the 1- and 2-
drenoceptors may alter the clinical profile of CHF or the
linical response to carvedilol (10,11). Despite these asso-
iative observations, it remains uncertain whether these
olymorphisms truly alter the physiologic response of the
yocardium to varying adrenergic drive. Furthermore, de-
pite the potential for polymorphisms of the pre-synaptic
2- and 2-adrenoceptors to modify the release of norepi-
ephrine from sympathetic nerve terminals, this has not
een investigated in humans. Accordingly, in the present
tudy we aimed to evaluate the effect of adrenergic receptor
olymorphisms on the response of myocardium to measured
evels of cardiac adrenergic drive, and secondly to evaluate
hether polymorphisms of pre-synaptic adrenoceptors
odified the rate of cardiac and systemic release of
orepinephrine.
ETHODS
ixty patients undergoing right heart catheterization for
valuation of CHF status and/or heart transplant assess-
ent participated in the study. The study group consisted
f 56 men and four women age 58  1 years (range 34 to
2 years). The etiology of CHF was ischemic cardiomy-
pathy in 48%, dilated cardiomyopathy in 47%, and other
auses in the remaining 5%. Subjects were all of Cauca-
ian background. The mean New York Heart Association
unctional class was 2.5 (range 2 to 4), the group mean
V ejection fraction was 19.9  1.0% (mean  SEM),
nd seven patients were in atrial fibrillation. The average
uration of HF was 4.7  1.3 years (range 2 to 25 years).
ll patients were treated with angiotensin-converting
nzyme inhibitors and diuretics, 79% received digoxin,
7% were treated with carvedilol, and 23% received
miodarone. Medications were withheld only on the
orning of the catheterization study to avoid potential
Abbreviations and Acronyms
CHF  congestive heart failure
HF  heart failure
PCR  polymerase chain reactionemodynamic instability. All patients gave written in- Aormed consent, and the study was approved by the
lfred Hospital Ethics Review Committee.
emodynamic evaluation and radiotracer measurement
f sympathetic nervous activity. A radial arterial line and
ight internal jugular venous sheath were inserted under
ocal anesthesia. This was followed by the measurement of
esting central hemodynamics, using a pulmonary artery
hermodilution catheter. A coronary sinus thermodilution
atheter (Webster Laboratories, Baldwin Park, California)
as subsequently positioned in the coronary sinus for blood
ampling and blood flow measurement. Total systemic and
ardiac norepinephrine spillover rates were determined ac-
ording to well-described methods previously reported by
ur group (12). In brief, 3H-labeled norepinephrine was
ontinuously infused (0.5 to 1 Ci/min) via a peripheral
ein to achieve steady-state plasma concentrations. The
lasma norepinephrine concentration in arterial and coro-
ary sinus blood was subsequently determined by high-
erformance liquid chromatography using electrochemical
etection. The plasma-specific activity of 3H-norepinephrine
as determined by timed collection of the detector cell
luant and subsequent radioactivity counting by liquid
cintillation spectroscopy.
drenoceptor genotyping. Genomic deoxyribonucleic acid
solated from peripheral blood was subjected to the polymerase
hain reaction (PCR) for the determination of the 1-
drenoceptor genotype at positions 49 and 389, the 2-
drenoceptor genotype at positions 16 and 27, and to establish
he presence or absence of the 2C-adrenoceptor 322–325
eletion polymorphism according to previously published
ethods (11,13–15). In brief, for the determination of the
1-adrenoceptor genotype at position 49 a 794-bp fragment
positions 1–794) of the 1-adrenoceptor gene was amplified
y PCR using the following primers: 5=-ATG GGC GGG
TG GTC-3= (sense) and 5=-GAA ACG GCG CTC GCA
CT GTC G-3= (antisense). The Ser49Gly polymorphism
as determined according to the Eco0109I digestion pattern.
or the 1-adrenoceptor genotype at position 389 a 547-bp
ragment of the 1-adrenoceptor gene was amplified by PCR
sing the following primers: 5=-CAT CAT CGT CTT CAC
C-3= (sense) and 5=-TGG GCT TCG AGT TCA CCT
C-3= (antisense). The Gly389Arg polymorphism was deter-
ined according to the BcgI digestion pattern. To determine
he 2-adrenoceptor genotype a 308-bp fragment of the
2-adrenoceptor gene was amplified by PCR using the follow-
ng primers: 5=-GCC TCC TTG CTGGCA CCC CAT-3=
sense) and 5=-GGA AGT CCA AAA CTC GCA CCA-3=
antisense). The Arg16Gly polymorphism was determined
ccording to the NcoI digestion pattern and the Gln27Glu
olymorphism was evaluated according to the pattern that
esulted from BbvI digestion. The 2C-adrenoceptor genotype
as determined according to the HaeIII digestion pattern of
he PCR product generated using the primers 5=-CAT CTA
CG AGT GGC CAA GCT-3= (sense) and 5=-AGC ACA
AG GTG AAG CGC TTC-3= (antisense).
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Adrenoceptor Genotype in CHF November 16, 2004:2008–15tatistical methods. Data are presented as mean values 
EM. Between-group comparisons were performed by un-
aired t test for two groups or one-way analysis of variance
or comparison of three groups. Linear regression analysis
as employed to investigate the relationship between inde-
endent variables. Analysis of covariance was employed to
ssess the influence of genotype on the relationship between
wo associated parameters. Chi-square analysis was per-
ormed to compare the distribution of categorical variables.
PSS version 11.0 (Chicago, Illinois) was used for statistical
nalysis. A p value 0.05 was considered statistically
ignificant.
ESULTS
n the present study we observed a 83% frequency of the
er49 allele and a 68% frequency of the Arg389 allele for the
1-adrenoceptor gene, together with a 38% frequency for
he Arg16 allele and a 56% frequency of the Gln27 allele for
he 2-adrenoceptor gene, consistent with previous studies
10,16). In respect of the 2C-adrenoceptor, 13% of the
tudy population was homozygous for the 2C (322–325del)
olymorphism, whereas no heterozygous individuals were
etected. In the present study cohort, patient utilization of
miodarone and carvedilol therapy was uniform across all
enotypes (data not shown).
drenoceptor genotype, hemodynamic and neurochemi-
al profile. For the entire study cohort, the group mean
ata were: heart rate 77  2 beats/min, mean arterial
ressure 80  1 mm Hg, mean pulmonary capillary wedge
ressure 18  1 mm Hg, mean pulmonary artery pressure
5 1 mm Hg, cardiac output was 4.1 0.1 l/min, plasma
orepinephrine concentration 2.8  0.2 pmol/ml, total
ystemic norepinephrine rate 5.3  0.5 nmol/min, and
ardiac norepinephrine spillover rate 288  31 pmol/min.
s shown in Table 1 the hemodynamic profile of our HF
ohort was quite homogeneous across all of the adrenocep-
or polymorphisms that were investigated. Our study had
able 1. Group Hemodynamic Profile According to Adrenocepto
Adrenoceptor Genotype n
Heart R
(beats/m
lpha-2C wt/wt 52 77
del/del 8 75 
eta-1 pos 49 Ser/Ser 42 75 
Ser/Gly 16 79
Gly/Gly 2 83
eta-1 pos 389 Arg/Arg 30 83
Arg/Gly 22 72
Gly/Gly 8 77
eta-2 pos 16 Arg/Arg 15 72 
Arg/Gly 15 77
Gly/Gly 30 83
eta-2 pos 27 Gln/Gln 19 80 
Gln/Glu 29 80
Glu/Glu 12 72
AP  mean arterial pressure; PCWP  pulmonary capillary wedge pressure.wo major aims: first to examine the interaction between tardiac sympathetic drive as assessed by the norepinephrine
pillover method and myocardial response as reflected by the
eart rate, and second to address the potential influence of
olymorphic variations of the pre-synaptic 2C- and 2-
drenoceptors on the release of norepinephrine.
To investigate the theoretical ability of polymorphisms
f the post-synaptic adrenoceptors (1 and 2) to modify
he heart rate response to neuronally released norepi-
ephrine, we first investigated the relationship between
eart rate and plasma catecholamines and catecholamine
pillover rates. As shown in Figures 1A and 1B, modestly
ignificant correlations were observed between heart rate
nd plasma norepinephrine and the total systemic nor-
pinephrine spillover rate. Of note, the relationship
etween heart rate and total norepinephrine spillover was
nfluenced by one outlying patient, and the relationship
ecame nonsignificant when this data point was censored
r  0.22, p  0.10). As shown in Figure 1C, a robust
elationship was observed between cardiac norepineph-
ine spillover rate and heart rate. To establish whether
he relationship between cardiac norepinephrine spillover
ate and heart rate was modified by polymorphisms of the
-adrenoceptors we performed an analysis of covariance
ccording to differing genotypes for the varying geno-
ypes. Under this analysis it was apparent the slope of the
elationship between cardiac norepinephrine spillover
ate and heart rate was significantly greater for patients
ith the 2-adrenoceptor genotype Arg/Arg at position
6, compared with the combined Arg/Gly and Gly/Gly
atient group (Fig. 2). The same relationship was also
bserved when patients treated with carvedilol (p  0.04)
r amiodarone (p  0.03) were excluded from the
nalysis, and similarly when patients in atrial fibrillation
ere excluded (p  0.04). A separate analysis of the three
ndividual 2- position 16 genotypes did not reveal
vidence of a gene “dose-effect” relationship. In contrast,
olymorphic variations of the 2-adrenoceptor at posi-
notype in Patients With Congestive Heart Failure
MAP
(mm Hg)
PCWP
(mm Hg)
Cardiac Output
(l/min)
79  1 17  1 4.4  0.2
86  4 17  3 4.7  0.7
79  2 17  1 4.3  0.2
82  2 19  3 4.0  0.3
79  5 11  2 5.9  1.5
83  2 16  2 4.4  0.2
76  2 17  2 4.1  0.3
80  2 22  2 4.1  0.4
80  3 15  2 4.2  0.3
80  2 18  3 4.6  0.3
78  3 18  2 4.3  0.3
81  2 18  2 4.5  0.3
79  2 17  2 4.7  0.4
79  2 17  2 4.1  0.3r Ge
ate
in)
3
3
3
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3ion 27 (Fig. 2) or the 1-adrenoceptor at positions 49
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November 16, 2004:2008–15 Adrenoceptor Genotype in CHFnd 389 (Fig. 3) showed no statistically significant
nfluence over the heart-rate-to-cardiac-norepinephrine
pillover relationship. There was no evidence of a specific
nteractive haplotype effect for either the 1- or 2-
drenoceptor on the relationship between cardiac adren-
rgic drive and heart rate.
Our second aim was to establish whether polymorphisms
f the pre-synaptic adrenoceptors had the capacity to
nfluence the rate of norepinephrine release from sympa-
igure 1. Scatterplots show the relationship between heart rate and plasma
orepinephrine (NE) (top panel), total systemic norepinephrine spillover
ate (SR) (middle panel), and cardiac norepinephrine spillover rate (lower
anel). The relationship between heart rate and total norepinephrine
pillover (middle panel) is influenced by an outlying patient; when
emoved r  0.22, p  0.10. bpm  beats/min.hetic nerve terminals. We first sought to establish the key gemodynamic driving factors for activation of cardiac sym-
athetic nerve activity. As previously observed, the key
emodynamic factor appeared to be the pulmonary capillary
edge pressure (Fig. 4), compared with either the mean
rterial pressure or cardiac output. As shown in Table 2,
olymorphic variations of the 2- or 2-adrenoceptors
howed no statistically significant influence over the rate of
pillover of norepinephrine from sympathetic nerves in the
eart specifically or more systemically as reflected by the
otal norepinephrine spillover rates. Analysis of covariance
as also employed to avoid the confounding effects of
ariations in contributing hemodynamic factors such as the
ulmonary capillary wedge pressure. Again, we were unable
o establish an effect of pre-synaptic adrenergic receptor
igure 2. Scatterplots demonstrate the relationship between cardiac nor-
pinephrine spillover (NE SR) and heart rate. The top panel indicates the
elationship according to 2-adrenoceptor genotype at position 16 and the
ower panel represents position 27. The dashed line in the top panel
ndicates the regression line for Arg/Arg individuals and the solid line in
he top panel indicates the regression line for the combined Arg/Gly and
ly/Gly patients. The slope of the line is significantly different (p 0.02).
pm  beats/min.enotype on the rate of release of norepinephrine for either
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Adrenoceptor Genotype in CHF November 16, 2004:2008–15he 2- or 2C-adrenoceptors (Fig. 5). In conjunction, there
as no evidence of a 2-adrenoceptor haplotype effect on
he cardiac norepinephrine spillover rate per se, or on the
elationship between wedge pressure and norepinephrine
pillover (data not shown).
ISCUSSION
t is now without doubt that the sympathetic nervous system
lays a pivotal role in the progression of CHF. In particular,
ctivation of the cardiac sympathetic nerves has been shown
n CHF to be linked to adverse outcome (2) and occurs early
n the development of left ventricular dysfunction (17).
learly, the antagonism of excess exposure to norepineph-
ine within the failing heart as afforded by the use of
-adrenoceptor antagonists has contributed greatly to the
anagement of the CHF patient. Recently a number of
olymorphic variations of both - and -adrenoceptors
ave been identified (10). A number of these have been
igure 3. Scatterplots demonstrating the relationship between cardiac
orepinephrine spillover (NE SR) and heart rate. The top panel indicates
he relationship according to 1-adrenoceptor genotype at position 49 and
he lower panel represents position 389.hown to have direct biochemical consequences, and some vave been demonstrated clinically to be associated with
harmacological response to -adrenoceptor agonists (18)
nd antagonists (11) or to be associated with the prevalence
nd clinical profile of HF (9,19).
Within the myocardium adrenergic receptors are located
n multiple cell types, including cardiomyocytes and inner-
igure 4. Scatterplots demonstrate the relationship between cardiac nor-
pinephrine spillover rate (NE SR) and pulmonary capillary wedge pressure
PCWP) (top panel), mean arterial (Art.) pressure (middle panel), and
ardiac output (lower panel).ating sympathetic neurons. In the present study, we wished
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November 16, 2004:2008–15 Adrenoceptor Genotype in CHFpecifically to assess the importance of functionally relevant
olymorphisms of the 1-, 2-, and 2-adrenoceptor in the
ontext of the interaction between sympathetic nerves and
he myocardium. We hypothesized that this interaction
ould, theoretically, be modified by genotype in two ways.
irst, polymorphisms of the 1- or 2-adrenergic receptors
ould influence the heart rate at a given level of adrenergic
able 2. Norepinephrine Spillover According to Adrenoceptor
enotype in Patients With Congestive Heart Failure
drenoceptor Genotype
Cardiac NE
SR (pmol/min)
Systemic NE
SR (nmol/min)
lpha-2C wt/wt 290 82 5.4  0.5
del/del 295 87 5.0  1.3
eta-2 pos 16 Arg/Arg 280 59 5.3  0.8
Arg/Gly 344 78 5.4  0.8
Gly/Gly 269 40 5.4  0.8
eta-2 pos 27 Gln/Gln 277  62 5.6  0.8
Gln/Glu 308  42 4.1  0.5
Glu/Glu 261 68 5.8  0.9
E  norepinephrine; SR  spillover rate.
igure 5. Scatterplot shows the relationship between pulmonary capillary
edge pressure (PCWP) and cardiac norepinephrine spillover rate (NE
R) according to 2C-adrenoceptor genotype (top panel), 2-adrenoceptort
enotype at position 16 (middle panel), and 2-adrenoceptor genotype at
osition 27 (lower panel).rive, and second, polymorphisms of adrenergic receptors
ocated pre-synaptically could modify the release of norepi-
ephrine for a given level of cardiac sympathetic nerve
ring.
In the context of our first question, we demonstrated a
trong relationship between the prevailing level of cardiac
drenergic drive as reflected by the cardiac norepinephrine
pillover rate and heart rate in patients with HF. When we
xamined the effect of 1- or 2-adrenoceptor genotype as
otential modifiers, we showed, for the first time, that
atients who were homozygous for the Arg residue at
osition 16 of the 2-adrenoceptor demonstrated a signifi-
antly greater heart rate for a given level of adrenergic input.
hese data are consistent with the known biochemical
rofile of polymorphisms at this locus. Specifically, the
ly16 polymorphism is associated with enhanced agonist-
romoted downregulation in contrast to Arg16 (20). At a
linical level, few studies have examined the interaction
etween stimuli that alter cardiac adrenergic drive and
emodynamic response in the context of adrenergic receptor
olymorphisms, and none has directly measured cardiac
drenergic drive as in the present study. In a previous study
agoner et al. (19) showed that the exercise response in
atients with CHF who had the 2-adrenoceptor Gly16
olymorphism had reduced exercise capacity, although in
heir study heart rate was no different at rest or during
xercise. Although in the present study we cannot comment
bout the role of polymorphisms of the -adrenoceptors in
he context of HF progression for a given level of adrenergic
rive, it is also noteworthy that unlike the 1-adrenoceptor,
t has been demonstrated that the 2-adrenoceptor does not
ndergo downregulation in HF (6). As such, the role
ssumed by polymorphisms of the myocardial 2-
drenoceptor may assume even greater relevance in the
athophysiology of CHF.
Our study is also the first to examine the relationship
etween 2C- and 2-adrenoceptor genotype and catechol-
mine release in human congestive HF. We quantitated the
ate of release of norepinephrine from cardiac sympathetic
erve terminals using the norepinephrine spillover tech-
ique, as previously characterized by our group. This study
as predicated on recent studies that have drawn an
ssociation between the presence of polymorphic variations
n the 2C- and 2-adrenoceptor and the prevalence or
everity of CHF (9,19) and the theoretical influence of these
olymorphisms on the pre-synaptic control of neurotrans-
itter release. Our study does not provide support for the
vidence that genetic polymorphisms of pre-synaptic adre-
oceptors play a role in the pathophysiology of CHF, but by
irtue of their apparent lack of effect on norepinephrine
elease from sympathetic nerves. In this study we also
ttempted to correct for possible variations in the levels of
ajor hemodynamic stimuli that might alter the rate of
ardiac sympathetic nerve firing.
The 2-adrenoceptor has long been known to regulatehe rate of release of norepinephrine from sympathetic nerve
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Adrenoceptor Genotype in CHF November 16, 2004:2008–15erminals, both in vitro and in vivo (8,21). Several polymor-
hisms of the various 2-adrenoceptors have been identi-
ed, but most recently the 2C-del 322–325 has been
scribed particular importance after the demonstration of an
ssociation between its presence and an increased incidence
f HF (9). In the present study we could not demonstrate
ny apparent relationship between the presence or absence
f this mutation and the rate of catecholamine release from
ympathetic nerves. Although functional data suggest this
utation is associated with reduction function (22), its
nfluence on catecholamine release has not been previously
ested in vivo or in vitro. In the present study, the apparent
ack of influence of the 2C-adrenoceptor polymorphism on
he rate of release of norepinephrine from the heart could
eadily be explained by a downregulation of the pre-synaptic
2-adrenoceptor in CHF, as we have previously shown (21).
Pre-synaptic 2-adrenoceptors have been proposed to
lay a facilitatory role in the release of norepinephrine
rom sympathetic nerve terminals in the heart, although this
emains controversial (23,24). As with the 2C-adrenoceptor,
everal polymorphisms of the 2-adrenoceptor that are asso-
iated with functional consequences have been described. In
articular, the Gly16 and Gln27 polymorphisms have been
hown to occur in a significant proportion of the population
nd are associated with increased agonist-induced down-
egulation (10). In the present study we did not observe a
elationship between the presence of either polymorphism
nd an altered norepinephrine spillover rate, suggesting that
ither the 2-adrenoceptor itself does not play a functional
ole in regulating norepinephrine release from sympathetic
erves in CHF, or that the documented biochemical effects
f the polymorphisms are of no physiologic significance
ith reference to the modulation of norepinephrine release.
n support of the former possibility, Lameris et al. (24)
ecently showed that an intracoronary infusion of epineph-
ine was without effect on the myocardial interstitial nor-
pinephrine concentration as assessed by microdialysis.
As such, given our current data, it is more likely that
tudies that have associated 2-adrenoceptor genotype and
easures of functional capacity and possibly outcome, relate
ore to the level of expression and function of myocardial
2-adrenoceptors. Consistent with this hypothesis, we have
ecently shown that the influence of carvedilol on left
entricular function in patients with CHF was related to the
2-adrenoceptor genotype at position 27 (11), whereas it
oes not alter the release of norepinephrine from the failing
eart.
tudy limitations. Our study is the first to specifically
xamine the interaction between adrenergic drive to the
ailing heart and the associated cardiac response in the
ontext of polymorphic variations in adrenergic receptors.
ur study was of an invasive nature, and as such, the
umber of subjects included was of a modest size. Accord-
ngly, it is conceivable that our study was not sufficiently
owered to detect the potential influences of certain of the
enotypes or their interactions with relevant drugs, includ-ng carvedilol and amiodarone. Digoxin use was also prev-
lent, although we have previously shown that digoxin does
ot appear to modify cardiac adrenergic drive (25). Further,
iven the cohort size, it was unlikely that our study would
ave detected any significant interactions between geno-
ypes. Moreover, in contrast to the study by Small et al. (9),
ur study population did not include an African American
ohort, thus limiting the number of individuals with the 2C
eletion polymorphism, thereby limiting further haplotype
nalysis. Larger studies would be required to meaningfully
nvestigate haplotype analysis of this nature.
onclusions. Our study has, for the first time, sought to
nvestigate the basis for previously reported associations
etween polymorphic variations in adrenergic receptors and
he frequency or severity of HF. Specifically, we employed
etailed radiotracer methodology to investigate the impact
f 2C- and 2-adrenoceptor genotype on the relationship
etween a given level of cardiac adrenergic drive and the
yocardial response to that stimulus, and to investigate the
nfluence of polymorphisms of pre-synaptic adrenergic re-
eptors on the rate of cardiac and total systemic norepineph-
ine spillover in the setting of human HF. Our studies
ndicate that the myocardium response to a given level of
drenergic drive can be modified by adrenergic receptor
enotype, whereas polymorphic differences in pre-synaptic
drenoceptor genotype do not modify the rate of norepi-
ephrine release from sympathetic nerves.
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